Literature DB >> 11798085

Rapid detection of macroprolactin in the form of prolactin-immunoglobulin G complexes by immunoprecipitation with anti-human IgG-agarose.

J Schiettecatte1, J De Schepper, B Velkeniers, J Smitz, A Van Steirteghem.   

Abstract

Immunoprecipitation with anti-human immunoglobulin G-agarose was evaluated for the detection of prolactin-immunoglobulin G (PRL-IgG) complexes in macroprolactinemic samples from hyperprolactinemic patients (prolactin measured using the automated Elecsys PRL assay; Roche Diagnostics, Mannheim, Germany). Using the polyethylene glycol (PEG) precipitation test on serum samples with PRL above 1000 mIU/l, we detected macroprolactin in 38 out of 175 samples with a recovery below 50%. Gel filtration chromatography on a subset of hyperprolactinemic samples confirmed that macroprolactin was the predominant immunoreactive form of PRL in samples which showed a recovery < or = 50%. In 37 out of 38 samples containing macroprolactin, immunoprecipitation with anti-human IgG (anti-hIgG)-agarose revealed a higher PRL-binding (19.1-91.3%) than in the sera containing monomeric PRL (< 10%). In conclusion, we found that PEG precipitation detected macroprolactin in 21.7% of samples with elevated PRL levels as measured by the Elecsys PRL assay, and that in the vast majority of these samples the presence of PRL-IgG complexes could be demonstrated by immunoprecipitation with anti-hIgG-agarose. In view of the high prevalence of PRL-IgG complexes in hyperprolactinemic patients and the simplicity of the test, immunoprecipitation with anti-hIgG-agarose might play a role in the routine laboratory handling of hyperprolactinemic samples, especially with regards to PRL assays where PEG causes interference.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11798085     DOI: 10.1515/CCLM.2001.200

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Disturbance of redox status enhances radiosensitivity of hepatocellular carcinoma.

Authors:  Chao Sun; Zhen-Hua Wang; Xiong-Xiong Liu; Li-Na Yang; Yali Wang; Yang Liu; Ai-Hong Mao; Yuan-Yuan Liu; Xin Zhou; Cui-Xia Di; Lu Gan; Hong Zhang
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

2.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

3.  Macroprolactinemia: the consequences of a laboratory pitfall.

Authors:  Erzsébet Toldy; Zoltán Löcsei; István Szabolcs; Miklós I Góth; Pál Kneffel; Dominika Szöke; Gábor L Kovács
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

Review 4.  Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis.

Authors:  Noor Azlin Azraini Che Soh; Najib Majdi Yaacob; Julia Omar; Aniza Mohammed Jelani; Noorazliyana Shafii; Tuan Salwani Tuan Ismail; Wan Norlina Wan Azman; Anis Kausar Ghazali
Journal:  Int J Environ Res Public Health       Date:  2020-11-06       Impact factor: 3.390

5.  Macroprolactinemia in a patient with invasive macroprolactinoma: a case report and minireview.

Authors:  Atanaska Elenkova; Zdravka Abadzhieva; Nikolai Genov; Vladimir Vasilev; Georgi Kirilov; Sabina Zacharieva
Journal:  Case Rep Endocrinol       Date:  2013-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.